News - Page 149 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

Post published:September 21, 2021
Post category:Press Release

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018

Post published:September 20, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics

Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics

Post published:September 17, 2021
Post category:Psychedelic Bulletin

Read more about the article Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Post published:September 16, 2021
Post category:Press Release

Read more about the article Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO

Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO

Post published:September 16, 2021
Post category:Press Release

Read more about the article MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

Post published:September 16, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

Post published:September 15, 2021
Post category:Press Release

Read more about the article atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

Post published:September 15, 2021
Post category:Press Release

Read more about the article Small Pharma Announces Engagement of Investor Relations Provider

Small Pharma Announces Engagement of Investor Relations Provider

Post published:September 15, 2021
Post category:Press Release

Read more about the article Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder

Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder

Post published:September 14, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.